Revolution Medicines
RVMD
282 hedge funds and large institutions have $8.45B invested in Revolution Medicines in 2024 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 123 increasing their positions, 59 reducing their positions, and 30 closing their positions.
259% more capital inflows, than outflows
Capital inflows: $1.65B | Capital outflows: $459M
108% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 59
107% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 30
28% more funds holding in top 10
Funds holding in top 10: 18 → 23 (+5)
10% more funds holding
Funds holding: 256 → 282 (+26)
3.71% more ownership
Funds ownership: 102.16% → 105.87% (+3.7%)
16% less call options, than puts
Call options by funds: $42.3M | Put options by funds: $50.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$169M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
+$97.5M |
| 4 |
Nextech Invest
Zurich,
Switzerland
|
+$65.8M |
| 5 |
Paradigm Biocapital Advisors
New York
|
+$62.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$29.3M |
| 2 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$25.4M |
| 3 |
Bellevue Group
Kuesnacht,
Switzerland
|
-$24.4M |
| 4 |
Casdin Capital
New York
|
-$20.9M |
| 5 |
Fred Alger Management
New York
|
-$19.8M |
RVMD Hedge Fund Activity: Q4 2024 in Review
282 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q4 2024, worth a combined $8.45B — up 9.1% from $7.74B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new RVMD positions and 30 closed out — a net gain of 32 holders — while 123 added to existing stakes and 59 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $169M. The largest seller was Wellington Management Group, cutting an estimated $29.3M.
- 282 institutional investors held Revolution Medicines (RVMD) as of Q4 2024, up from 256 in Q3 2024.
- Funds reported $8.45B of Revolution Medicines stock for Q4 2024, up 9.1% quarter-over-quarter.
- 62 funds opened new Revolution Medicines positions in Q4 2024 and 30 closed out, a net change of +32 holders.
- The largest Revolution Medicines buyer in Q4 2024 was Janus Henderson Group, an estimated $169M added.
- The largest Revolution Medicines seller in Q4 2024 was Wellington Management Group, an estimated $29.3M sold.
Based on aggregated 13F filings for Q4 2024.